
Kontigo Care - Intensifying business and sales efforts in 2025

Redeye has revised its near-term estimates and valuation following the Q4 report, which showed resilient sales and MRR despite a challenging macroeconomic backdrop. The company is now prioritising business expansion and sales acceleration in 2025, driving its shift toward a more product- and commercially focused organisation. A strengthened cash position provides additional support for this transformation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Kontigo Care - Intensifying business and sales efforts in 2025](#)